+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
ID06714526

Genetic Testing to Guide Medication Choice Versus Standard Clopidogrel Treatment in Adults With Symptomatic Brain Artery Narrowing After Stroke

Led by Sunnybrook Health Sciences Centre · Updated on 2025-11-20

100

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of genetic testing to guide medication choice in adults who have had a stroke caused by intracranial atherosclerotic disease ICAD. This condition involves plaque buildup in brain arteries, reducing blood flow and increasing stroke risk. The study focuses on patients aged 40 and older who recently experienced a stroke or transient ischemic attack TIA due to ICAD. The goal is to see if genetic testing can help select the best blood-thinning medication and if this approach is feasible and safe for patients. Participants will be randomly assigned to one of two groups. One group will receive standard care, taking clopidogrel plus aspirin daily for 90 days. The other group will undergo a genetic test using the Genomadix Cube to determine if they can process clopidogrel effectively. Based on the test, they will either take clopidogrel plus aspirin or switch to ticagrelor plus aspirin for 90 days. Brain scans and clinical assessments will be conducted at the start and after 90 days to monitor for new strokes and evaluate function and memory. During the study, participants will have brain imaging, cognitive tests, and questionnaires to assess their neurological function and quality of life. Researchers will track recruitment rates, study completion, and any adverse events, including bleeding or stroke. Secondary measures include changes in stroke volume, cognitive scores, and daily living activities. The study will last about 90 days per participant, helping inform future larger trials on personalized stroke treatment through genetic testing.

CONDITIONS

Brief Title

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

Research Team

M

Mark I Boulos, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here